Berlin

Longevity for VCs: Fountain of Growth or Mirage of Hype?

The longevity sector promises to radically redefine aging – not just as a biological process, but as an investable market. With breakthroughs in biotech, AI-driven diagnostics, and preventative medicine, the vision of a longer, healthier human lifespan is becoming tangible. For VCs, this opens a new frontier: a potential multi-trillion-dollar opportunity at the intersection of science, healthcare, and consumer demand. But with regulatory hurdles, long timelines, and ethical complexity, the question remains – is longevity the next great moonshot, or a seductive detour from scalable returns?

Tuesday, April 29, 2025